Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study

Turk J Gastroenterol. 2021 Dec;32(12):1019-1028. doi: 10.5152/tjg.2021.201171.

Abstract

Aims: To evaluate patient profile for epidemiological and clinicopathological characteristics and potential risk/prognostic factors in newly diagnosed hepatocellular carcinoma (HCC) patients across Turkey.

Methods: A total of 547 patients (mean (SD) age 62.6 (10.3) years, 81.9% were males) were included in this registry study. Data on patient characteristics, etiologies of HCC, laboratory values, and tumor characteristics and stages were recorded at study enrollment.

Results: HBV infection (68.2%) was the leading etiology, followed by HCV infection (17.2%), HDV infection (5.5%), alcohol (6.4%), and NAFLD (3.5%), as the major etiologies. Considering that 51.6% of the patients had >5 cm HCC, 44% were Child-Pugh B/C and 57% were BCLC B-D, it appears that a significant group of HCC patients were diagnosed at advanced stages. Of 540 patients, 271 (50.2%) were referred or applied with the diagnosis of HCC. Patients with HCC at presentation had larger tumor size (median (min-max) 6.6 (0-30) vs. 4.8 (0-90) cm, P < .001) and more advanced BCLC stage (Stage C-D in 40.8% vs. 26.4%, respectively, P = .005), compared to patients who were diagnosed during follow-up.

Conclusions: Our findings revealed that HBV infection was the leading etiology and a moderate-to-advanced disease was evident in more than half of patients at the time of diagnosis. HCC patients diagnosed at follow-up had smaller tumor size and earlier BCLC stage.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Abdominal Pain / etiology*
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular / diagnosis*
  • Carcinoma, Hepatocellular / epidemiology
  • Female
  • Humans
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / epidemiology
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / complications*
  • Prospective Studies
  • Registries
  • Turkey / epidemiology
  • Weight Loss

Grants and funding

This study was supported by Bayer Turk. We thank Cagla Ayhan, MD and Sule Oktay, MD, PhD, from KAPPA Consultancy Training Research Ltd., Istanbul, who provided editorial support funded by Bayer Turk.